46.JPG)
Global RNA-based Therapeutics Market is valued at USD 12.4 Billion in 2024 and is predicted to reach USD 22.6 Billion by the year 2034 at a 6.5% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
- The growing biopharmaceutical sector, characterized by increased investment and interest in innovative therapies, is propelling the RNA-based therapeutics market.
- The entry of new biotech startups focused on RNA therapeutics is expanding the competitive landscape and driving technological advancements.
- North America dominated the market and accounted for a global revenue share in 2024.
- Ensuring consistent quality and purity of RNA-based products during large-scale production is critical and challenging.
RNA-based therapeutics is a moderately new class of treatment representing significant potential and growth for the treatment of severe and rare diseases. RNA-based therapeutics are gaining significance for several disease targets, such as genetic disorders, HIV, cancer, etc. The growing prevalence of chronic diseases and lack of proper treatment is generating high demand for the development of RNA-based therapeutics. For instance, according to WHO, cancer ranked number two as a cause of death, and about 9.6 million deaths occurred in 2018. Moreover, the rising prevalence of genetic diseases, hematological disorders are generating the global demand for RNA-based therapeutics. Moreover, advancements and development of promising technologies such as SMaRT technology, antisense technology, and RNAi interference technology are expected to generate immense opportunities for the growth of the market in the coming years.
The strong base on ongoing studies for RNA-based therapeutics and the presence of a large number of players investing in the market is estimated to propel the growth of the market significantly over the estimated timeframe. In July 2018, about 320 ongoing clinical studies for RNA-based therapeutics were registered. The introduction of these potential therapies in the coming years is expected to significantly boost the market's overall growth. However, challenges connected with the commercialization of RNA-based therapies such as drug delivery and toxicity may substantially hamper the market growth. Moreover, the high cost of development may hinder the growth of the market. The lack of substitute treatment selections for rare diseases further enhancing the demand for RNA-based therapeutics globally. Additionally, a growing focus of legislative bodies on evolving reimbursement policies is fueling the development of RNA’s molecules process.
Competitive Landscape
Some major key players in the RNA-based Therapeutics Market:
- Akcea Therapeutics Inc,
- Biogen Inc.,
- Noxxon Pharma,
- Ophthotech Corporation,
- Olix Pharmaceuticals,
- GlaxoSmithKline Plc,
- Sanofi S.A,
- Alnylam Pharmaceuticals,
- Ionis Pharmaceuticals,
- Benitec Biopharma Ltd,
- Acuitas Therapeutics,
- Arbutus Biopharma,
- Silence Therapeutics Plc,
- Enzon Pharmaceuticals Inc,
- Bio-Path Holdings Inc.,
- Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc.),
- Antisense Therapeutics Ltd.,
- Gene Signal,
- Gradalis,
- iCo Therapeutics,
- Lorus Therapeutics (Aptose Biosciences),
- miRagen Therapeutics,
- Mirna Therapeutics Inc,
- Marina Biotech,
- OncoGeneX Pharmaceuticals,
- Quark Pharmaceuticals,
- Pharmaxis Ltd,
- Rexahn Pharmaceuticals,
- Regulus Therapeutics,
- Rxi Pharmaceuticals,
- Santaris Pharma A/S (Roche),
- Sarepta Therapeutics,
- Sirnaomics Inc.,
- Dicerna Pharmaceuticals
Market Segmentation
The Global RNA-Based Therapeutics Market is segmented based on product, type, indication and end-user. By Product segment, the market is divided into Vaccines and Drugs. Whereas, By Type, the market is categorized into mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, RNA Aptamer, and Other Therapeutics. The segmentation includes Indication segment which is further classified into Infectious Diseases, Rare Genetic Diseases/Hereditary Diseases, Oncology, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), and Others. The End User segment comprises Hospitals and Clinics, Research Settings.
Recent Developments:
- In Sept 2024, Ionis Pharmaceuticals, Inc. entered into an agreement with Roche for two early-stage studies, the details of which have not been revealed. These projects prioritize the development of investigational drugs that target RNA and are intended to treat Alzheimer's disease (AD) and Huntington's disease (HD). The firms utilized Ionis' proficiency in identifying pharmaceuticals that specifically addressed the underlying cause of central nervous system ailments while using Roche's extensive worldwide knowledge in the development and marketing of treatments for illnesses of the nervous system.
The RNA-based Therapeutics Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 12.4 Billion |
|
Revenue Forecast In 2034 |
USD 22.6 Billion |
|
Growth Rate CAGR |
CAGR of 6.5% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, Type, Indication, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Akcea Therapeutics Inc, Biogen Inc., Noxxon Pharma, Ophthotech Corporation, Olix Pharmaceuticals, GlaxoSmithKline Plc, Sanofi S.A, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Benitec Biopharma Ltd, Acuitas Therapeutics, Arbutus Biopharma, Silence Therapeutics Plc, Enzon Pharmaceuticals Inc, Bio-Path Holdings Inc., Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc.), Antisense Therapeutics Ltd., Gene Signal, Gradalis, iCo Therapeutics, Lorus Therapeutics (Aptose Biosciences), miRagen Therapeutics, Mirna Therapeutics Inc, Marina Biotech, OncoGeneX Pharmaceuticals, Quark Pharmaceuticals, Pharmaxis Ltd, Rexahn Pharmaceuticals, Regulus Therapeutics, Rxi Pharmaceuticals, Santaris Pharma A/S (Roche), Sarepta Therapeutics, Sirnaomics Inc., and Dicerna Pharmaceuticals |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
